Fennec Pharmaceuticals (FRX) Competitors

Cronos Group (TSE:CRON) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Which has preferable valuation & earnings, CRON or FRX?

Fennec Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$130.28M	10.58	-C$32.78M	C$0.05	72.00
Fennec Pharmaceuticals	C$33.30M	9.97	-C$800.44K	-C$0.45	-26.51

Which has more risk & volatility, CRON or FRX?

Cronos Group has a beta of 1.208662, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 2.091843, suggesting that its stock price is 109% more volatile than the S&P 500.

Do analysts rate CRON or FRX?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Do institutionals & insiders have more ownership in CRON or FRX?

4.6% of Cronos Group shares are owned by institutional investors. Comparatively, 13.8% of Fennec Pharmaceuticals shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is CRON or FRX more profitable?

Fennec Pharmaceuticals has a net margin of -2.30% compared to Cronos Group's net margin of -42.65%. Fennec Pharmaceuticals' return on equity of 29.94% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-42.65%	-4.40%	-3.73%
Fennec Pharmaceuticals	-2.30%	29.94%	8.88%

Does the media prefer CRON or FRX?

In the previous week, Fennec Pharmaceuticals had 2 more articles in the media than Cronos Group. MarketBeat recorded 2 mentions for Fennec Pharmaceuticals and 0 mentions for Cronos Group. Fennec Pharmaceuticals' average media sentiment score of 0.75 beat Cronos Group's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cronos Group	Neutral
Fennec Pharmaceuticals	Positive

Summary

Fennec Pharmaceuticals beats Cronos Group on 10 of the 15 factors compared between the two stocks.